| abstract |
The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salt thereof, wherein R 1 is selected from the group consisting of (C 1 -C 6) alkyl, - (CR 3 R 4) t (C 3 -C 12) cycloalkyl, - (CR 3 R 4) t ( C 6 -C 12 aryl, and - (CR 3 R 4) t (4-10) -linked heterocyclyl; b is selected from the group consisting of 0, 1 and 2; t is selected from the group consisting of 0, 1, 2, 3, 4 and 5; T is a (6-10) -linked heterocyclyl containing at least one nitrogen atom; R2 is selected from the group consisting of H, (C1-6) alkyl, - (CR3R) t (C3-C12) cycloalkyl, - (CR3R4) t (C6-C12) aryl, and - (CR3R4) t (4-10 ) -linked heterocyclyl; R 3 and R 4 are each independently selected from H and (C 1 -C 6) alkyl, the carbon atoms of T, R 1, R 2, R 3 and R 4 each being optionally substituted with 1 to 5 R 5 groups; R5 is defined in the claims. The compounds of the present invention are 11 (hsd-1) inhibitors and are therefore considered useful in the treatment of diabetes, obesity, glaucoma, osteoporosis, cognitive disorders, immune disorders, depression, hypertension and metabolic diseases. |